News

Hosted on MSN1mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has ... the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. C3G is a progressive and ultra-rare kidney disease that is ...
Hosted on MSN1mon
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis NVS obtains FDA ... disease. Approximately 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis. The approval Vanrafia marks the third ...
MedCity News15d
Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition
Novartis has made kidney disorders ... trying to slow disease progression. The lone therapeutic is tolvaptan, brand name Jynarque, an Otsuka Pharmaceutical drug approved by the FDA in 2018 for ...
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal
Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...
pharmaphorum5d
FDA sets September review date for Calliditas' rare kidney disease drug
Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA has now ... Berger’s disease, in which antibodies accumulate in the kidney, causing ...
NJBIZ15d
Novartis to acquire Regulus in $1.7B kidney drug deal
Novartis plans ... known as miroRNAs. The drug is expected to enter a late-stage study this year to test it for the treatment of autosomal dominant polycystic kidney disease.
Benzinga.com15d
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...
Medindia1mon
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of ...
Yahoo Finance1mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
On Thursday, the U.S. Food and Drug Administration (FDA ... for Fabhalta and its second within the Novartis kidney disease portfolio since August 2024, when Fabhalta was granted accelerated approval ...
Yahoo Finance15d
Novartis to acquire Regulus in deal for kidney disease drug
Novartis will ... pharmaceutical firm a drug prospect called farabursen, which recently completed a Phase 1b study in people with autosomal dominant polycystic kidney disease, or ADPKD.
Yahoo Finance15d
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal
(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...